Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02206360 · ClinicalTrials.gov registry record
Pancreatic Cancer Early Detection Program
A clinical trial of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by White Plains Hospital.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT02206360 is a study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is active but no longer recruiting, run by White Plains Hospital. The registered enrollment target is 100 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02206360, a study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is active but no longer recruiting, sponsored by White Plains Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk. Our inclusion criteria has a strong focus on the risk for pancreatic cancer imparted by the presence of hereditary cancer genes, as well as by family history. Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Endoscopic Ultrasound
Study Locations (1)
New York
- White Plains Hospital - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-04 |
| Est. Completion | 2024-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02206360
The ClinicalTrials.gov registry entry for NCT02206360 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (75% lower). The listed sponsor is White Plains Hospital, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT02206360 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02206360 about?
NCT02206360 is a clinical study titled "Pancreatic Cancer Early Detection Program". Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancre...
What is the current status of trial NCT02206360?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2014-04. Estimated completion is 2024-06.
What conditions does trial NCT02206360 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Cancer, Lynch Syndrome, Familial Pancreatic Cancer.
What interventions are being tested in trial NCT02206360?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Endoscopic Ultrasound (PROCEDURE).
Who is sponsoring clinical trial NCT02206360?
This trial is sponsored by White Plains Hospital, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02206360 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.